3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Completed
4
Recruiting
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
4
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, AIDS-Related
1
HIV Infections
1
Dendritic Cell Sarcoma, Interdigitating
1
Interventions
Cyclophosphamide
956
Radiotherapy
847
Cisplatin
757
Gemcitabine
657
Carboplatin
603
Docetaxel
598
Paclitaxel
585
Bevacizumab
580
Fluorouracil
504
Oxaliplatin
458
Rituximab
453
Surveys and Questionnaires
449
Capecitabine
440
Dexamethasone
428
Doxorubicin
424
Etoposide
411
Irinotecan
389
Cytarabine
376
Filgrastim
369
pembrolizumab
330
Leucovorin
305
Nivolumab
296
fludarabine phosphate
294
Melphalan
288
Magnetic Resonance Spectroscopy
281
Peripheral Blood Stem Cell Transplantation
279
Blood Specimen Collection
279
Methotrexate
276
Lenalidomide
276
Cetuximab
270
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Completed
×
OTHER
×
efavirenz
×
Clear all
NCT00964171
2025-08-28
PANTER
Institut Bergonié
Phase 2
Completed
19 enrolled
11 charts
NCT00964002
2022-05-16
FAVE
Institut Bergonié
Phase 2
Completed
61 enrolled
6 charts
NCT01878890
2021-01-27
ESCALE
Institut Bergonié
Phase 1
Completed
25 enrolled
11 charts
NCT00799136
2013-09-12
CATCH
Ontario Clinical Oncology Group (OCOG)
Phase 2
Completed
6 enrolled